title: Efficacy of dendritic cells matured early with OK-432 (Picibanil), prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory prostate cancer cell line.
abstract: Dendritic cells (DCs) are potent antigen-presenting cells. OK432 (Picibanil) was introduced as a potent stimulator of DC maturation in combination with prostaglandin-E(2) and interferon-alpha. We compared the efficacy of a DC-prostate cancer vaccine using early-mature DCs stimulated with OK432, PGE2 and INF-alpha (OPA) with that of vaccines using other methods. On days 3 or 7 of DC culture, TNF-alpha (T), TNF-alpha and LPS (TL) or OPA were employed as maturation stimulators. DU145 cells subjected to heat stress were hybridized with mature DCs using polyethyleneglycol. T cells were sensitized by the hybrids, and their proliferative and cytokine secretion activities and cytotoxicity were measured. The yields of early-mature DCs were higher, compared to yields at the conventional maturation time (P<0.05). In the early maturation setting, the mean fusion ratios, calculated from the fraction of dual-positive cells, were 13.3%, 18.6%, and 39.9%, respectively (P=0.051) in the T only, TL, and OPA-treated groups. The function of cytotoxic T cells, which were sensitized with the hybrids containing DCs matured early with OPA, was superior to that using other methods. The antitumor effects of DC-DU145 hybrids generated with DCs subjected to early maturation with the OPA may be superior to that of the hybrids using conventional maturation methods.
authors.affiliation: Department of Urology, College of Medicine, Hallym University, Hallym Sacred Heart Hospital, Anyang, Korea.
authors.forename: Changhee
authors.initials: C
authors.lastname: Yoo
authors.forename: Hyun-Ah
authors.initials: HA
authors.lastname: Do
authors.forename: In Gab
authors.initials: IG
authors.lastname: Jeong
authors.forename: Hongzoo
authors.initials: H
authors.lastname: Park
authors.forename: Jung-Jin
authors.initials: JJ
authors.lastname: Hwang
authors.forename: Jun Hyuk
authors.initials: JH
authors.lastname: Hong
authors.forename: Jin Seon
authors.initials: JS
authors.lastname: Cho
authors.forename: Myong-Soo
authors.initials: MS
authors.lastname: Choo
authors.forename: Hanjong
authors.initials: H
authors.lastname: Ahn
authors.forename: Choung-Soo
authors.initials: CS
authors.lastname: Kim
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D015232:Dinoprostone / Q000494:pharmacology*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D016898:Interferon-alpha / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000276:immunology*; D010641:Phenotype; D010844:Picibanil / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D007155:Immunologic Factors; D016898:Interferon-alpha; D008070:Lipopolysaccharides; D010844:Picibanil; D015232:Dinoprostone
references.citation: Immunol Lett. 2005 Nov 15;101(2):154-9
references.pmid: 15993950
references.citation: J Immunol. 1997 Mar 15;158(6):2919-25
references.pmid: 9058830
references.citation: Anticancer Res. 2002 Jul-Aug;22(4):2137-45
references.pmid: 12174895
references.citation: Eur J Immunol. 1997 Nov;27(11):3031-8
references.pmid: 9394834
references.citation: J Immunol. 2007 Jan 1;178(1):613-22
references.pmid: 17182602
references.citation: Biomed Pharmacother. 2006 May;60(4):156-60
references.pmid: 16647239
references.citation: J Exp Med. 1997 Oct 20;186(8):1183-7
references.pmid: 9379142
references.citation: J Immunother. 2007 May-Jun;30(4):359-69
references.pmid: 17457211
references.citation: Acta Odontol Scand. 2001 Jun;59(3):124-30
references.pmid: 11501880
references.citation: Int J Oncol. 2006 Nov;29(5):1263-8
references.pmid: 17016660
references.citation: Int J Cancer. 2004 May 1;109(5):685-90
references.pmid: 14999775
references.citation: Vox Sang. 2003 Apr;84(3):228-36
references.pmid: 12670372
references.citation: J Immunol. 1998 Sep 15;161(6):3042-9
references.pmid: 9743369
references.citation: Cancer Immunol Immunother. 2003 Apr;52(4):207-14
references.pmid: 12669245
references.citation: J Immunother. 2006 Jan-Feb;29(1):67-77
references.pmid: 16365602
references.citation: J Exp Med. 1994 Oct 1;180(4):1263-72
references.pmid: 7523569
references.citation: Med Oncol. 2004;21(2):155-65
references.pmid: 15299188
references.citation: J Immunol. 2007 Oct 1;179(7):4874-83
references.pmid: 17878387
references.citation: Apoptosis. 2006 Sep;11(9):1513-24
references.pmid: 16738802
references.citation: J Immunother. 2004 Jul-Aug;27(4):265-72
references.pmid: 15235387